Skyward Specialty Q1: Apollo Integration On Track, Thesis Unchanged

What happened

Skyward Specialty Insurance Group reported Q1 2026 results, with underwriting performance consistent with management's full-year guidance of a 90.5%-91.5% combined ratio and Apollo syndicate management fees trending toward the $30-$35 million target. The quarter marked the first full period post-Apollo acquisition, providing early validation of the capital-light fee stream and the group's ability to maintain underwriting discipline while scaling. However, the financial statements remain subject to purchase accounting finalization, and the increased leverage from the acquisition (notes payable of $471.5M at year-end) introduces tighter covenant constraints that investors should monitor. Overall, the report does not alter the base case but reinforces the need for continued execution over the next two quarters.

Implication

Maintain position but watch for combined ratio above 93% or syndicate fees below $25M annualized. If Q1 trend persists, the stock could re-rate toward $48 base value. However, debt covenants and incomplete purchase accounting warrant caution; a trim above $52 is prudent.

Thesis delta

Q1 2026 results align with the pre-existing thesis, with no material upside or downside surprise. The integration appears on track, but the absence of finalized purchase accounting and the early stage of fee realization keep the thesis unchanged. The next catalyst is Q2 2026 reporting when cost synergies and fee trends become clearer.